Cargando…

Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy Dependent DDI of Dabrafenib Metabolism

Dabrafenib inhibits the cell proliferation of metastatic melanoma with the oncogenic BRAF(V600)-mutation. However, dabrafenib monotherapy is associated with pERK reactivation, drug resistance, and consequential relapse. A clinical drug-dose determination study shows increased pERK levels upon daily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albrecht, Marco, Kogan, Yuri, Kulms, Dagmar, Sauter, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875124/ https://www.ncbi.nlm.nih.gov/pubmed/35214043 http://dx.doi.org/10.3390/pharmaceutics14020310

Ejemplares similares

Computational models of melanoma
por: Albrecht, Marco, et al.
Publicado: (2020)

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI
por: Jones, Nicholas S., et al.
Publicado: (2019)

Anticoagulation in COVID-19: DDI Perspective
por: Khiali, Sajad, et al.
Publicado: (2020)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
por: Atkinson, Victoria G., et al.
Publicado: (2021)

Ddi1 is a ubiquitin-dependent protease
por: Yip, Matthew C. J., et al.
Publicado: (2020)

Identification of New IκBα Complexes by an Iterative Experimental and Mathematical Modeling Approach
por: Konrath, Fabian, et al.
Publicado: (2014)

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study
por: Manzano, José L., et al.
Publicado: (2023)

Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 Proteases
por: Mótyán, János András, et al.
Publicado: (2020)

Hepatoma Formation in ddY Mice with Chronic Schistosomiasis japonica
por: Amano, Teruaki, et al.
Publicado: (1988)

Detailed Dissection of UBE3A-Mediated DDI1 Ubiquitination
por: Elu, Nagore, et al.
Publicado: (2019)

Pacemaker-induced tachycardia in a DDI-programmed ICD: What is the mechanism?
por: Jafri, Haseeb, et al.
Publicado: (2015)

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
por: Zahir, Hamim, et al.
Publicado: (2022)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017)

Modeling time delay in the NFκB signaling pathway following low dose IL-1 stimulation
por: Witt, Johannes, et al.
Publicado: (2011)

Analysing the Role of UVB-Induced Translational Inhibition and PP2Ac Deactivation in NF-κB Signalling Using a Minimal Mathematical Model
por: Witt, Johannes, et al.
Publicado: (2012)

The First Described Case of Occupational Anthracofibrosis in the USA
por: Rangelov, Kamen, et al.
Publicado: (2014)

Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
por: Yoneyama, Tomoki, et al.
Publicado: (2020)

Describing dengue epidemics: Insights from simple mechanistic models
por: Aguiar, Maíra, et al.
Publicado: (2012)

HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites
por: White, Rhian E., et al.
Publicado: (2011)

The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction
por: Koizumi, Shun, et al.
Publicado: (2016)

The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma
por: Op, Mélanie, et al.
Publicado: (2022)

The protease DDI2 regulates NRF1 activation in response to cadmium toxicity
por: Ribeiro, Sérgio T., et al.
Publicado: (2022)

DDI-MuG: Multi-aspect graphs for drug-drug interaction extraction
por: Yang, Jie, et al.
Publicado: (2023)

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
por: Grant, Joshuaine, et al.
Publicado: (2023)

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
por: Aglietta, Massimo, et al.
Publicado: (2021)

Dabrafenib and its potential for the treatment of metastatic melanoma
por: Menzies, Alexander M, et al.
Publicado: (2012)

Dabrafenib/trametinib: Cardiac toxicity: case report
Publicado: (2021)

Vemurafenib and Dabrafenib Downregulates RIPK4 Level
por: Madej, Ewelina, et al.
Publicado: (2023)

Mechanism of PP2A-mediated IKKβ dephosphorylation: a systems biological approach
por: Witt, Johannes, et al.
Publicado: (2009)

ReaDDy 2: Fast and flexible software framework for interacting-particle reaction dynamics
por: Hoffmann, Moritz, et al.
Publicado: (2019)

TGx-DDI, a Transcriptomic Biomarker for Genotoxicity Hazard Assessment of Pharmaceuticals and Environmental Chemicals
por: Li, Heng-Hong, et al.
Publicado: (2019)

Recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2
por: Ibtisam, Ibtisam, et al.
Publicado: (2023)

Describing the relationship between occupational and non-occupational physical activity using objective measurement
por: JaKa, Meghan M., et al.
Publicado: (2015)

The Role of AKT/mTOR Pathway in Stress Response to UV-Irradiation: Implication in Skin Carcinogenesis by Regulation of Apoptosis, Autophagy and Senescence
por: Strozyk, Elwira, et al.
Publicado: (2013)

A 3D Organotypic Melanoma Spheroid Skin Model
por: Müller, Ines, et al.
Publicado: (2018)

Cell death and regeneration in Dresden—the 27th meeting of the European Cell Death Organization
por: Linkermann, Andreas, et al.
Publicado: (2019)

Identifying and targeting cancer-specific metabolism with network-based drug target prediction
por: Pacheco, Maria Pires, et al.
Publicado: (2019)

Phenotype characterization of human melanoma cells resistant to dabrafenib
por: Cordaro, Fabiola Gilda, et al.
Publicado: (2017)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v23ck2h4ak1kn3ednept14pu2e